However, clinicopathologic factors such as age, tumor stage, expression of estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) do not predict the proportional risk reduction for recurrence or death conferred by adjuvant chemotherapy (CT) (Peto et al., 2012). This evidence concerns the gene ERBB2 and neoplasm.